NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
Aarhus, Denmark, 26 September 2023– NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that the first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Brain | Clinical Trials | Denmark Health | Neurology | Pharmaceuticals | Spinal Muscular Atrophy